Royce & Associates LP decreased its stake in LifeMD, Inc. (NASDAQ:LFMD – Free Report) by 96.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,573 shares of the company’s stock after selling 616,551 shares during the quarter. Royce & Associates LP’s holdings in LifeMD were worth $57,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of LFMD. BlackRock Inc. boosted its position in LifeMD by 8.0% during the second quarter. BlackRock Inc. now owns 3,034,535 shares of the company’s stock valued at $12,533,000 after purchasing an additional 225,510 shares during the last quarter. State Street Corp raised its stake in shares of LifeMD by 22.6% during the 2nd quarter. State Street Corp now owns 1,318,784 shares of the company’s stock worth $5,447,000 after purchasing an additional 243,376 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of LifeMD during the 2nd quarter valued at about $1,338,000. Russell Investments Group Ltd. lifted its holdings in shares of LifeMD by 5,801.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock valued at $1,300,000 after buying an additional 309,436 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of LifeMD in the 2nd quarter valued at approximately $1,078,000. Institutional investors and hedge funds own 35.52% of the company’s stock.
LifeMD Price Performance
Shares of LFMD stock opened at $1.45 on Friday. LifeMD, Inc. has a one year low of $1.38 and a one year high of $5.38. The stock has a fifty day moving average price of $2.47 and a 200 day moving average price of $3.53. The stock has a market cap of $69.84 million, a P/E ratio of -24.08 and a beta of 2.19.
LifeMD (NASDAQ:LFMD – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. LifeMD had a negative net margin of 0.25% and a negative return on equity of 188.63%. The firm had revenue of $44.63 million for the quarter, compared to analyst estimates of $48.84 million. Equities research analysts anticipate that LifeMD, Inc. will post -0.48 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the stock. Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Mizuho decreased their price target on LifeMD from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Friday, November 13th. B. Riley Financial initiated coverage on LifeMD in a report on Friday, September 11th. They set a “buy” rating and a $8.00 price objective on the stock. HC Wainwright lowered their price target on LifeMD from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Lake Street Capital lowered their price target on LifeMD from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 13th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, LifeMD has a consensus rating of “Moderate Buy” and a consensus target price of $6.71.
Get Our Latest Research Report on LifeMD
About LifeMD
LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.
Further Reading
- Five stocks we like better than LifeMD
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.
